The latest report by IMARC Group, titled “Aminoglycosides Market Report by Product (Neomycin, Tobramycin, Gentamicin, Amikacin, Paromomycin, Streptomycin, Kanamycin, and Others), Route of Administration (Injectables (Parenteral), Intra-mammary, Topical, Oral, and Others), Application (Veterinary, Skin Infection, Respiratory Diseases, UTI and Pelvic Diseases, and Others), and Region 2023-2028“, The global aminoglycosides market size reached US$ 1.58 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 1.90 Billion by 2028, exhibiting a growth rate (CAGR) of 2.96% during 2023-2028.

Factors Affecting the Growth of the Global Aminoglycosides Industry:

• Increasing Prevalence of Bacterial Infections:

A key driver of the aminoglycosides market is the persistent and growing prevalence of bacterial infections worldwide. Aminoglycosides, a class of antibiotics known for their effectiveness against a wide range of Gram-negative bacteria, play a crucial role in combating these infections. Factors contributing to the rising infection rates include antibiotic-resistant strains, nosocomial infections, and an aging population with weakened immune systems. Aminoglycosides are used in the treatment of severe bacterial infections such as sepsis, pneumonia, and urinary tract infections. The need for effective antibiotics to address these medical challenges fuels the demand for Aminoglycosides and propels market growth.

• Rising Research and Development:

Continued research and development efforts in the field of antibiotics, including Aminoglycosides, are driving market expansion. Scientists are working on developing new formulations and derivatives of Aminoglycosides to enhance their efficacy, reduce toxicity, and combat antibiotic resistance. These efforts aim to address the limitations associated with traditional Aminoglycoside antibiotics, such as nephrotoxicity and ototoxicity. Additionally, research focuses on optimizing dosing regimens and exploring combination therapies to maximize therapeutic outcomes. The pursuit of novel Aminoglycoside antibiotics and improved treatment protocols keeps the market dynamic and responsive to emerging infectious diseases and evolving resistance patterns, driving innovation and market growth.

• Increasing Surgical Procedures:

The rising number of surgical procedures performed globally is a significant driver of the aminoglycosides market. Aminoglycosides are often administered as prophylactic antibiotics before surgery to reduce the risk of postoperative infections. With the growth of healthcare infrastructure, an aging population, and an increase in elective surgeries, the demand for Aminoglycosides as part of perioperative care is on the rise. Surgical procedures such as joint replacements, cardiac surgeries, and organ transplants require effective infection prevention measures, and Aminoglycosides play a vital role in achieving this goal. As surgical volumes increase, so does the consumption of Aminoglycoside antibiotics, contributing to the expansion of the market.

Competitive Landscape with Key Player:

• Huvepharma NV
• Kremoint Pharma Pvt. Ltd.
• Novartis AG
• Pfizer Inc.
• Teva Pharmaceutical Industries Ltd
• Vega Group company limited

For an in-depth analysis, you can refer sample copy of the report: https://www.imarcgroup.com/aminoglycosides-market/requestsample

Report Segmentation:

The report has segmented the market into the following categories:

Breakup by Product:

• Neomycin
• Tobramycin
• Gentamicin
• Amikacin
• Paromomycin
• Streptomycin
• Kanamycin
• Others

Gentamicin dominates the market due to the increasing prevalence of infectious diseases.

Breakup by Route of Administration:

• Injectables (Parenteral)
• Intra-mammary
• Topical
• Oral
• Others

Injectable (parenteral) hold the largest market share as it ensures accurate dosing and consistent bioavailability.

Breakup by Application:

• Veterinary
• Skin Infection
• Respiratory Diseases
• UTI and Pelvic Diseases
• Others

Respiratory diseases dominate the market due to the efficacy of the product in treating severe respiratory infections.

Market Breakup by Region:

• North America (United States, Canada)
• Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
• Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
• Latin America (Brazil, Mexico, Others)
• Middle East and Africa

Asia Pacific leads the market due to the increasing burden of infectious diseases, necessitating effective antimicrobial treatment options.

Aminoglycosides Market Trends:

Increasing antibiotic resistance among bacterial pathogens is driving the exploration of combination therapies, where aminoglycosides are often used in combination with other antibiotics. This approach aims to enhance treatment efficacy while minimizing the development of resistance. Research into optimized combinations and dosing regimens is ongoing. Besides, aminoglycosides are being explored for their potential in treating emerging and highly drug-resistant infections, including those caused by Gram-negative superbugs. The urgency to find effective treatments for such infections, which are often associated with high mortality rates, has led to increased research and clinical trials involving aminoglycosides.

Note: If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.

About Us

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact US

IMARC Group

134 N 4th St. Brooklyn, NY 11249, USA

Email: sales@imarcgroup.com

Tel No:(D) +91 120 433 0800

United States: +1-631-791-1145 | United Kingdom: +44-753-713-2163